CIK 0000920148
- Large accelerated filer
LABCORP HOLDINGS INC.
Sign in to watch- Ticker
- LH
- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 992588107
- Phone
- +1 336-229-1127
- Business address
- 358 S MAIN ST, BURLINGTON, NC, 27215
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS, NATIONAL HEALTH LABORATORIES HOLDINGS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,377,699
- in 4 filings, $108K under 10b5-1 plans
Net −$1,377,699. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-11 | NEUPERT PETER M Director | Exercise or conversion | +742 | 10,996 | ||
| 2023-02-11 | NEUPERT PETER M Director | Exercise or conversion · Restricted Stock Unit | −742 | 849 | ||
| 2023-02-11 | Parham Richelle P Director | Exercise or conversion | +742 | 7,587 | ||
| 2023-02-11 | Parham Richelle P Director | Exercise or conversion · Restricted Stock Unit | −742 | 849 | ||
| 2023-02-11 | Wengel Kathryn E Director | Exercise or conversion | +742 | 1,345 | ||
| 2023-02-11 | Wengel Kathryn E Director | Exercise or conversion · Restricted Stock Unit | −742 | 849 | ||
| 2023-02-11 | Williams R Sanders Director | Exercise or conversion | +742 | 7,173 | ||
| 2023-02-11 | Williams R Sanders Director | Exercise or conversion · Restricted Stock Unit | −742 | 849 | ||
| 2023-02-11 | BERBERIAN LANCE EVP, CIO & CTO | Exercise or conversion | +290 | 20,253 | ||
| 2023-02-11 | BERBERIAN LANCE EVP, CIO & CTO | Exercise or conversion · Restricted Stock Unit | −290 | 1,827 | ||
| 2023-02-11 | Caveney Brian J EVP, President of Diagnostics | Exercise or conversion | +423 | 16,536.76 | ||
| 2023-02-11 | Caveney Brian J EVP, President of Diagnostics | Exercise or conversion · Restricted Stock Unit | −423 | 2,681 | ||
| 2023-02-11 | Kirchgraber Paul R CEO, Covance Drug Development | Exercise or conversion | +483 | 14,211 | ||
| 2023-02-11 | Kirchgraber Paul R CEO, Covance Drug Development | Exercise or conversion · Restricted Stock Unit | −483 | 3,001 | ||
| 2023-02-11 | EISENBERG GLENN A Chief Financial Officer, EVP | Exercise or conversion | +723 | 35,835 | ||
| 2023-02-11 | EISENBERG GLENN A Chief Financial Officer, EVP | Exercise or conversion · Restricted Stock Unit | −723 | 13,764 | ||
| 2023-02-11 | Schechter Adam H President & CEO | Exercise or conversion | +2,656 | 24,351 | ||
| 2023-02-11 | Schechter Adam H President & CEO | Exercise or conversion · Restricted Stock Unit | −2,656 | 16,828 | ||
| 2023-02-11 | Schroeder Mark S EVP, President-Diagnostics Lab | Exercise or conversion | +423 | 7,110.4 | ||
| 2023-02-11 | Schroeder Mark S EVP, President-Diagnostics Lab | Exercise or conversion · Restricted Stock Unit | −423 | 2,681 |
Page 40 of 41 · 816 trades